Step 1 topics → Hematology and Oncology → Factor V Leiden and Protein C/S Deficiency

Factor V Leiden and Protein C/S Deficiency

USMLE Step 1 trap: Misattributes Factor V Leiden thrombosis to direct activation rather than resistance to Protein C inactivation. Factor V Leiden carries a point mutation (R506Q) that makes Factor Va resistant to cleavage by activated Protein C, preventing its inactivation and sustaining thrombin generation.

Factor V Leiden and Protein C/S deficiency are the two most-tested hereditary thrombophilias on USMLE Step 1. Both cause venous thromboembolism through loss of a key anticoagulant brake — but the mechanisms are distinct and the exam exploits that distinction relentlessly. The critical misconception to fix first: students think Factor V Leiden activates the coagulation cascade. It doesn't — it prevents inactivation of an already-active Factor Va. The R506Q point mutation removes the APC cleavage site, so the brake never engages and thrombin generation continues unchecked. Similarly, Protein C doesn't inhibit thrombin directly; it targets Factors Va and VIIIa — confusing these targets gets the warfarin skin necrosis mechanism wrong.

USMLE Step 1 tests this at two levels. First, pure mechanism: given a patient with recurrent DVT/PE and a specific lab or genetic finding, identify why thrombosis occurs. Second, clinical application: warfarin-induced skin necrosis is the classic Protein C deficiency scenario, and students consistently get it wrong because they don't know why the timing matters. The exam will give you a patient starting warfarin who develops hemorrhagic skin lesions within the first few days — that's the signal. The tricky part is understanding it's not a direct drug toxicity; it's a transient procoagulant window created by differential half-lives.

The biggest traps: (1) students think Factor V Leiden activates something, when it actually resists inactivation — a passive mechanism, not active; (2) students think Protein C inhibits thrombin directly, when its actual targets are Factors Va and VIIIa; (3) students think warfarin skin necrosis is about vessel damage rather than a pharmacokinetic gap. Get these three mechanistic points solid and you'll handle every vignette this topic throws at you.

From real student decks
70%have cards covering this topic
41%have mature cards
1.0median lapses in 14 days

Common misconceptions

Common mistake
Wrong: Factor V Leiden causes thrombosis by directly activating the coagulation cascade.
Right: Factor V Leiden carries a point mutation (R506Q) that makes Factor Va resistant to cleavage by activated Protein C, preventing its inactivation and sustaining thrombin generation.
Factor V Leiden doesn't crank up the coagulation cascade — it just prevents the off-switch from working. Normally, activated Protein C cleaves Factor Va at Arg506, inactivating it and slowing thrombin generation. The R506Q mutation changes that cleavage site so APC can't cut it. Factor Va just keeps running, thrombin keeps being made, and the clot propagates. Think of it as a car with a stuck gas pedal because the brakes can't engage, not a car with a bigger engine.
Common mistake
Wrong: Warfarin-induced skin necrosis occurs because warfarin directly damages skin vessels.
Right: Warfarin-induced skin necrosis in Protein C deficiency occurs because Protein C's short half-life causes it to fall first, creating a transient procoagulant state before anticoagulant factors are depleted.
Warfarin doesn't poison skin vessels — it creates a temporary window where the patient is paradoxically MORE procoagulant than before. Protein C is a vitamin K-dependent anticoagulant with a very short half-life (~8 hours). When warfarin is started, Protein C falls first before the procoagulant factors (II, IX, X) are sufficiently depleted. In a patient already low on Protein C (deficiency), this gap is dramatic enough to trigger microvascular thrombosis in the skin, causing the characteristic hemorrhagic necrosis. This is why you always bridge with heparin when starting warfarin in high-risk patients.
Common mistake
Wrong: Protein C inactivates thrombin directly.
Right: Protein C (activated by thrombin-thrombomodulin complex) inactivates Factors Va and VIIIa, not thrombin itself, thereby dampening the amplification loop of coagulation.
Protein C does not inhibit thrombin directly — that's antithrombin's job. Activated Protein C (along with its cofactor Protein S) targets Factors Va and VIIIa, the two critical cofactors that massively amplify thrombin generation on phospholipid surfaces. By degrading Va and VIIIa, Protein C shuts down the amplification loops of the cascade. If you confuse this with direct thrombin inhibition, you'll mis-predict what happens in deficiency states and get the warfarin skin necrosis mechanism wrong.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Given a patient with recurrent venous thromboembolism and a specific mutation, explain exactly why Factor V Leiden causes a hypercoagulable state — tracing it through the R506Q point mutation, APC resistance, and sustained Factor Va activity leading to excess thrombin generation.
  2. Given a patient with Protein C deficiency who starts warfarin and develops skin necrosis within days, explain why this happens — including Protein C's normal targets (Factors Va and VIIIa), its short half-life relative to procoagulant factors, and the transient procoagulant state that results.

Can you avoid these mistakes?

A 32-year-old woman with a history of two unprovoked DVTs is found to have Factor V Leiden. Her sister asks if she's at risk. What is the inheritance pattern of Factor V Leiden, and at the molecular level, why does this mutation lead to thrombosis rather than bleeding?
A 45-year-old man with known Protein C deficiency is started on warfarin for a new DVT without heparin bridging. Three days later he develops painful, hemorrhagic skin lesions on his thigh. What is the mechanism, and what step in management was missed?
Activated Protein C is described as an anticoagulant. A student says 'so it breaks down thrombin.' What are the actual targets of activated Protein C, and what cofactor does it require to function?
Two patients have defects in the same anticoagulant pathway: one has Factor V Leiden, the other has Protein C deficiency. Both develop DVTs. Explain how each defect disrupts the same physiologic process but through mechanistically different means.

Related topics

Coagulation Cascade and PT/PTT Interpretation Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →